Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.
Simon A RuleW JurczakM JerkemanC RusconiM TrnenyF OffnerD CaballeroC JoaoM Witzens-HarigG HessI Bence-BrucklerSeok-Goo ChoC ThieblemontW ZhouT HenningerJ GoldbergJ VermeulenM DreylingPublished in: Leukemia (2018)